Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

65.87 -1.86 (-2.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 23.65% to $2.81 during Friday's regular session. As of 12:30 EST, BioLine Rx's stock is trading at a... 
Via Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
Exposures COVID-19
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma
Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with... 
Via Benzinga
Exposures Product Safety
Halozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q3 revenue of $115.8 million compared to $65.3 million a year ago, beating the consensus of $101.94 million.... 
Via Benzinga
Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcript
HALO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 Guidance
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q2 revenue of $136.5 million compared to $55.2 million a year ago, beating the consensus of $103.16 million.... 
Via Benzinga
Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript
HALO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Halozyme Therapeutics: Q2 Earnings Insights
Shares of Halozyme Therapeutics (NASDAQ:HALO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 247.37% over the... 
Via Benzinga
Analyzing Halozyme Therapeutics's Unusual Options Activity
On Friday, shares of Halozyme Therapeutics (NASDAQ:HALO) saw unusual options activity. After the option alert, the stock price moved down to $42.55. Sentiment: BEARISH Option... 
Via Benzinga
Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma
The FDA has approved Janssen Biotech Inc's, a unit of Johnson & Johnson (NYSE: JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for multiple... 
Via Benzinga
Exposures Product Safety
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal
GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme... 
Via Benzinga
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
From ViiV Healthcare
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021
Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Nymox Pharmaceutical (NASDAQ:NYMX... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021
Upgrades B of A Securities upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Neutral to Buy. In the first quarter, Kosmos Energy showed an EPS of $0.08,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021
Upgrades For CEVA Inc (NASDAQ:CEVA), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first quarter, CEVA had an EPS of $0.01, compared to year... 
Via Benzinga
Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript
HALO earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Earnings Outlook for Halozyme Therapeutics
On Monday, May 10, Halozyme Therapeutics (NASDAQ:HALO) will release its latest earnings report. Here is Benzinga's outlook for the company. Net Income, Earnings, And Earnings Per... 
Via Benzinga
Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. Krystal Biotech stock fits that bill. 
Via Investor's Business Daily
Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90
Cel-Sci shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Biotech Applied Molecular Transport Stock Earns Relative Strength Rating Upgrade
On Tuesday, Applied Molecular Transport stock reached an important technical milestone, seeing its Relative Strength Rating jump to 91 from 87. 
Via Investor's Business Daily
Arvinas Stock Clears Technical Benchmark With 80-Plus Relative Strength Rating
Arvinas shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.